Cue Biopharma - CUE Price-to-Projected Revenue Ratio

The success of Cue Biopharma, Inc. (CUE) is based on the efficiency of R&D projects amid a high burn rate, which is further complicated by geopolitical barriers in global science. The change in the forward P/S ratio clearly demonstrates the valuation amplitude, while the 3.10 indicator confirms the current level. Investors should consider the uncertainty of partnership payments and a potential liquidity shortfall prior to the drug commercialization stage.

CUE (Cue Biopharma Inc.) Projected Price to Revenue history from 07/04/2022 to 11/14/2026

Comprehensive metric breakdowns and analytics for Cue Biopharma (CUE)

- market price and analyst price targets:

Price Chart Cue Biopharma, Inc.|CUE - Broker Consensus Forecast

- issuer market value details:

Market Value Cue Biopharma, Inc.|CUE - Total Enterprise Value

- book value of equity indicators:

Accounting Value per Share Cue Biopharma|CUE - Book Value of Business|Market Cap to Net Assets Ratio cuebiopharma.com|CUE - Aggregate Business Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

CUE - Profit After Tax|Future Profit Cue Biopharma, Inc.|CUE - Market Cap to Earnings|Forward P/E Multiple Cue Biopharma Inc.|CUE - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Cue Biopharma|CUE - Operating profit EBITDA|Net earnings per share (EPS TTM) Cue Biopharma|CUE - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cuebiopharma.com|CUE - Earnings per share increase in current year|Earnings growth forecast for next year Cue Biopharma, Inc.

- revenue and sales proceeds data:

CUE - Company Revenue|Projected Sales Volume Cue Biopharma Inc.|CUE - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Cue Biopharma, Inc.

Initial company analysis:CUE (Cue Biopharma, Inc.)

Identifying fundamentally resilient assets requires analyzing the expected business value relative to its future cash flows. This indicator measures the market price of one dollar of projected revenue, which allows for an assessment of liquidity flows into risky biopharmaceuticals from Cue Biopharma, Inc. (CUE) considering their complex supply chains, while analyzing valuation stability through a forward price-to-sales ratio.

Key competitors

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|alxoncology.com - Forward Price-to-Revenue Multiple|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP